Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

被引：0
|
作者：
Day, Kathleen A. [1 ]
Ament, Michael [2 ]
Stauffer, Virginia L. [1 ]
Skljarevski, Vladimir [1 ]
Zhang, Qi [1 ]
Pearlman, Eric M. [1 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Ament Headache Ctr, Denver, CO 80206 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O31
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab Among Patients with Episodic and Chronic Migraine
    Ruff, D.
    Ford, J.
    Starling, A. J.
    Detke, H. C.
    Nichols, R.
    Port, M.
    Aurora, S. K.
    HEADACHE, 2019, 59 : 101 - 101
  • [42] REDUCTION IN THE SEVERITY OF HEADACHE IN PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE WITH FREMANEZUMAB TREATMENT
    Ashina, M.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    CEPHALALGIA, 2018, 38 : 62 - 63
  • [43] Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
    Dodick, David W.
    Doty, Erin G.
    Aurora, Sheena K.
    Ruff, Dustin D.
    Stauffer, Virginia L.
    Jedynak, Jakub
    Dong, Yan
    Pearlman, Eric M.
    CEPHALALGIA, 2021, 41 (03) : 340 - 352
  • [44] Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
    Yoshihisa Tatsuoka
    Takao Takeshima
    Akichika Ozeki
    Taka Matsumura
    Neurology and Therapy, 2021, 10 : 265 - 278
  • [45] Misused and Misleading: "100% Response Rate" to Galcanezumab in Patients With Episodic Migraine
    Steiner, Timothy J.
    Tfelt-Hansen, Peer
    HEADACHE, 2019, 59 (04): : 626 - 626
  • [46] Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study
    Tatsuoka, Yoshihisa
    Takeshima, Takao
    Ozeki, Akichika
    Matsumura, Taka
    NEUROLOGY AND THERAPY, 2021, 10 (01) : 265 - 278
  • [47] Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine
    Quintana, Simone
    Russo, Marco
    Manzoni, Gian Camillo
    Torelli, Paola
    NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5757 - 5758
  • [48] Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine
    Chen, Po-Wei
    Karlsson, Mats O.
    Ueckert, Sebastian
    Pritchard-Bell, Ari
    Hsu, Cheng-Pang
    Dutta, Sandeep
    Ahamadi, Malidi
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (12): : 1988 - 2000
  • [49] Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine
    Simone Quintana
    Marco Russo
    Gian Camillo Manzoni
    Paola Torelli
    Neurological Sciences, 2022, 43 : 5757 - 5758
  • [50] Effectiveness of Galcanezumab on sleep, migraine and multidimensional patient-reperted outcome measures: A real-world experience in Turkish patients with episodic migraine and chronic migraine
    Aydinlar, Elif Ilgaz
    Soyukibar, Tuba Erdogan
    Dikmen, Pinar Yalinay
    CEPHALALGIA, 2023, 43 (1supp) : 243 - 243
12345